Objective To investigate the effects of triamcinolone acetonide combined with tanshinone ⅡA (Monomer of tanshinone)injection on oral submucous fibrosis(OSF)and the effect of serum TGF-β1 and IL-6 on patients.Methods 92 patients with OSF,w ho came to the hospital for treatment from April 2013 to April 2016,were selected and randomly divided into control group(46 cases)and experimental group(46 ca-ses).They were respectively treated with triamcinolone acetonide and triamcinolone acetonide combined with tanshinone injection.The two groups were treated for 3 courses and were followed up for 12 months.The VAS scores and mouth opening were compared between the two groups before the treatment and 2,4,6,and 12 months after the treatment,The serum TGF-β1,IL-6,lesion area and the changes of quality of life oral health impact scale(OHIP-14)scores of two groups were compared before and after treatment.Results 6 months after follow-up,the maximum mouth opening of the two groups was significantly increased than that before treatment,and improvement speed and improvement degree of the experimental group were better than those of the control group(P<0.05).After 2,4,6 and 12 months follow-up,the VAS scores of the two groups were significantly lower than those before treatment,and the experimental group were significantly lower than those of the control group(P<0.05),but the VAS score of two groups after 12 months increased than that after 6 months,and the control group was more obvious(P<0.05).After treatment,the levels of TGF-β1 and IL-6 of the experimental group were significantly lower than those of the control group and before the treat-ment(P<0.05);After treatment,the lesion area of the experimental group was significantly lower than that of the control group,and the OHIP-14 score was significantly higher than that of the control group,and the difference was significant compared with this group before treatment(P<0.05).Conclusion The local injec-tion treatment of triamcinolone and tanshinone injection has godd efficacy of OSF patients,and significantly re-duces the levels of TGF-β1 and IL-6 in serum.%目的 探究曲安奈德联合丹参酮ⅡA(丹参酮单体之一)注射液治疗口腔黏膜下纤维化(OSF)的效果及对血清转化生长因子β1(TGF-β1)、白介素-6(IL-6)水平的影响.方法 选择2013年4月至2016年4月间于该院就诊的92例OSF患者,按治疗方法分为对照组(46例)和试验组(46例),分别给予单纯曲安奈德、曲安奈德联合丹参酮ⅡA注射液局部注射治疗3个疗程,并进行为期12个月的随访,比较两组患者治疗前和第2、4、6、12个月随访的张口度和VAS评分情况,以及治疗前后的 TGF-β1、IL-6、病损面积和口腔健康影响程度量表(O HIP-14)评分等的变化情况.结果 随访6个月,对照组和试验组患者的最大张口度较治疗前均有明显增加,试验组患者的改善速度和改善程度明显优于对照组,差异有统计学意义(P<0.05);随访第2、4、6、12个月,两组患者的VAS评分较治疗前均有明显降低,试验组降低更为明显,差异有统计学意义(P<0.05),两组12个月的VAS评分较6个月出现升高,对照组更为明显,差异有统计学意义(P<0.05);治疗后,试验组TGF-β1和IL-6水平明显低于对照组和本组治疗前,差异有统计学意义(P<0.05);治疗后,试验组的病损面积显著低于对照组、OHIP-14评分明显高于对照组,与本组治疗前比较,差异有统计学意义(P<0.05).结论 在OSF患者中应用曲安奈德联合丹参酮注射液局部注射治疗具有较好的疗效,能明显降低血清中TGF-β1和IL-6的水平.
展开▼
